Stockscreener 앱 받기
2.35
4.44%
0.10
전일 마감가:
$2.25
열려 있는:
$2.2
하루 거래량:
83,911
Relative Volume:
1.01
시가총액:
$8.93M
수익:
-
순이익/손실:
$-6.24M
주가수익비율:
-0.4207
EPS:
-5.5853
순현금흐름:
$-8.09M
1주 성능:
-1.67%
1개월 성능:
+8.80%
6개월 성능:
-33.43%
1년 성능:
-77.29%
1일 변동 폭
$2.1323
$2.40
1주일 범위
$2.1323
$2.41
52주 변동 폭
$1.69
$11.02
Alzamend Neuro Inc Stock (ALZN) Company Profile
명칭
Alzamend Neuro Inc
전화
844-722-6333
주소
3500 LENOX RD. NE, ATLANTA
ALZN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
2.35 | 8.55M | 0 | -6.24M | -8.09M | -5.5853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-01 | 개시 | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc 주식(ALZN)의 최신 뉴스
Aug Sectors: Is Alzamend Neuro Inc stock heavily shortedJuly 2025 News Drivers & Weekly High Return Opportunities - baoquankhu1.vn
Bond Watch: Can Alzamend Neuro Inc stock beat market expectations this quarterQuarterly Growth Report & Capital Protection Trade Alerts - Bộ Nội Vụ
Alzamend Neuro (NASDAQ:ALZN) Stock Price Down 2.5% – Should You Sell? - Defense World
Can Alzamend Neuro Inc. stock beat analyst upgradesJuly 2025 Outlook & Safe Entry Point Identification - ulpravda.ru
ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Will Alzamend Neuro Inc. stock attract ESG investorsJuly 2025 Outlook & Precise Swing Trade Entry Alerts - Улправда
Will Alzamend Neuro Inc. stock return to pre crisis levelsJuly 2025 Short Interest & Safe Entry Zone Tips - ulpravda.ru
What technical charts say about Alzamend Neuro Inc. stockQuarterly Performance Summary & Reliable Price Breakout Alerts - ulpravda.ru
Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Alzamend Neuro, Inc.Common Stock (NQ: ALZN - FinancialContent
Momentum Shift: Will Alzamend Neuro Inc stock attract ESG investorsEarnings Performance Report & Stepwise Trade Signal Implementation - Bộ Nội Vụ
Ascendiant Sticks to Their Buy Rating for Alzamend Neuro (ALZN) - The Globe and Mail
Ascendiant Capital Maintains Alzamend Neuro (ALZN) Buy Recommendation - Nasdaq
ALZN: Ascendiant Capital Lowers Price Target, Maintains Buy Rati - GuruFocus
Decliners Report: Why Alzamend Neuro Inc. stock is recommended by analystsQuarterly Market Review & Detailed Earnings Play Strategies - Улправда
Will Alzamend Neuro Inc. stock deliver long term returnsWeekly Profit Analysis & Consistent Profit Trade Alerts - Улправда
Is Alzamend Neuro Inc. stock attractive for ETFs2025 Support & Resistance & Community Verified Trade Signals - Улправда
Can Alzamend Neuro Inc. stock maintain growth trajectoryWeekly Trade Analysis & Risk Managed Trade Strategies - DonanımHaber
Alzamend Neuro Earnings Notes - Trefis
Why Alzamend Neuro Inc. stock is recommended by analystsQuarterly Growth Report & Verified Momentum Watchlists - Улправда
Can Alzamend Neuro Inc. stock sustain market leadershipJuly 2025 Chart Watch & Consistent Return Investment Signals - Улправда
Alzamend Neuro, Inc. SEC 10-Q Report - TradingView
Is Alzamend Neuro Inc stock attractive for passive investorsWeekly Investment Summary & Weekly Top Gainers Alerts - BỘ NỘI VỤ
Why Alzamend Neuro Inc. stock remains undervaluedJuly 2025 Analyst Calls & High Accuracy Trade Alerts - Newser
Alzamend Neuro (ALZN) Stock Analysis Report | Financials & Insights - Benzinga
Alzamend Neuro Mourns Loss of Director Andrew Woo - MSN
Is Alzamend Neuro Inc. stock attractive for passive investors2025 Earnings Impact & Daily Profit Focused Stock Screening - BỘ NỘI VỤ
Alzamend Neuro: Will Topline Data Spark Investor Interest? - RTTNews
Alzamend Neuro's AL001 formulation highlights its potential to treat disorders such a Alzheimer's - SelectScience
What margin trends mean for Alzamend Neuro Inc. stockWeekly Market Outlook & Verified Swing Trading Watchlists - newser.com
Why Alzamend Neuro Inc. stock could see breakout soonProduct Launch & High Return Trade Opportunity Guides - newser.com
Why Alzamend Neuro Inc. stock could benefit from AI revolutionTrade Risk Report & Daily Profit Maximizing Tips - newser.com
Can Alzamend Neuro Inc. stock sustain revenue growthMarket Risk Analysis & Pattern Based Trade Signal System - newser.com
Will Alzamend Neuro Inc. stock rally after Fed decisionsJuly 2025 Closing Moves & Safe Swing Trade Setup Alerts - newser.com
Will Alzamend Neuro Inc. stock reach all time highs in 2025Exit Point & Daily Technical Forecast Reports - newser.com
Alzamend completes clinical portion of phase II trial for lithium therapy - Investing.com Nigeria
Published on: 2025-11-19 13:20:00 - newser.com
Alzamend Neuro announces passing of board member Andrew H. Woo By Investing.com - Investing.com Australia
Comparing Alzamend Neuro Inc. in custom built stock radarsWeekly Risk Summary & Weekly Momentum Picks - newser.com
Alzamend Neuro announces completion of clinical portion of phase II clinical trial of AL001 "lithium in brain" study conducted at Massachusetts General Hospital - MarketScreener
Alzamend rises after completing mid-stage brain lithium study - TradingView
Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data - Stock Titan
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants - Benzinga
Alzamend Neuro Inc (ALZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alzamend Neuro Inc 주식 (ALZN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Horne William B. | Director |
Dec 19 '25 |
Sale |
2.12 |
3,333 |
7,059 |
0 |
| McGrath Lynne Fahey | Director |
Oct 23 '25 |
Sale |
2.29 |
30 |
69 |
25 |
| AULT MILTON C III | Director |
Oct 08 '25 |
Sale |
2.44 |
101,394 |
247,158 |
28,657 |
| AULT MILTON C III | Director |
Oct 09 '25 |
Sale |
2.32 |
20,397 |
47,390 |
8,260 |
| AULT MILTON C III | Director |
Oct 06 '25 |
Sale |
2.45 |
82,033 |
201,268 |
26,227 |
| AULT MILTON C III | Director |
Oct 07 '25 |
Sale |
2.49 |
57,379 |
142,954 |
68,848 |
| AULT MILTON C III | Director |
Oct 03 '25 |
Sale |
2.44 |
65,903 |
160,889 |
8,260 |
| AULT MILTON C III | Director |
Oct 01 '25 |
Sale |
2.35 |
36,777 |
86,378 |
94,849 |
| AULT MILTON C III | Director |
Oct 02 '25 |
Sale |
2.39 |
20,686 |
49,522 |
74,163 |
| AULT MILTON C III | Director |
Sep 29 '25 |
Sale |
2.31 |
38,324 |
88,490 |
35,192 |
4.73%
0.92%
자본화:
|
볼륨(24시간):